Work

LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.

Year: 2018

Type: article

Abstract: . BCL-2 was regulated by LMO4 and mediated the promoting role of LMO4 in trastuzumab resistance of HER2 positive breast cancer cells. High level of LMO4 was associated with worse clinicopathological parameters (including tumor size and histological grade) and lower survival rate in HER2 positive breast cancer patients. LMO4 therefore could be used as a target to develop diagnostic and therapeutic methods for human HER2 positive breast cancer.

Source: Europe PMC (PubMed Central)

Authors: Keshuo Ding, Zhengsheng Wu, Xiaocan Li, Youjing Sheng, Xiaonan Wang, Sheng Tan

Institutions: Anhui Medical University, Second Affiliated Hospital of Anhui Medical University, University of Science and Technology of China

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W3006441332

FWCI: 0.939

Cites: 53

Cited by: 14

Related to: 10